Reflex testing for EGFR at the time of the advanced/metastatic disease diagnosis was performed in half of the participating sites (n = 13; 52%), and reflex T790M mutation testing at the time of progression in one third of sites (n = 9; 36%). This evidence concerns the gene EGFR and metastatic neoplasm.